PT. RICHMOND, Calif., Sept. 28 /PRNewswire/ -- Transcept
 Pharmaceuticals, Inc., a specialty pharmaceutical company deriving
 significant new patient benefits from proven CNS drugs, today announced
 that Glenn A. Oclassen, President and Chief Executive Officer, is scheduled
 to present at the 2007 BIO Investor Forum at the Palace Hotel in San
 Francisco on Thursday, October 11, 2007 at 3:00 PM Pacific Time.
     About Transcept Pharmaceuticals
     Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company
 deriving significant new patient benefits from proven CNS drugs. The
 company's development projects leverage new understanding of CNS conditions
 to provide additional uses and enhanced clinical benefits for existing
 active agents. Transcept's lead compound, Intermezzo(TM) (zolpidem tartrate
 lozenge), is a low dose formulation of zolpidem that is currently in late
 phase 3 clinical trials for the treatment of insomnia in patients who
 awaken in the middle of the night and have difficulty returning to sleep.
 TO-2060 is a novel, fixed-combination dose of olanzapine and ondansetron
 that is being evaluated for the treatment of dopamine associated
 psychiatric disorders (DAPD). TO-2060 is currently the subject of an
 initial proof of concept trial in the treatment of alcohol use disorder
 (AUD). For more information, please visit the Company's website at:
 http://www.transcept.com.
 
 

SOURCE Transcept Pharmaceuticals, Inc.